Literature DB >> 24068004

Performance monitoring of mycobacterium tuberculosis dried culture spots for use with the GeneXpert system within a national program in South Africa.

N Gous1, B Cunningham, B Kana, W Stevens, L E Scott.   

Abstract

The use of dried culture spots (DCSs) has been reported in the verification of GeneXpert instruments as being "fit for purpose" for the South African National implementation program. We investigated and compared the performance of the DCSs for verification across different bulk batches, testing the settings and cadre of staff, and the Xpert MTB/RIF assay version. Four bulk batches (V005 to V008) were used to prepare (i) 619 DCS panels for laboratory testing on G3 or G4 cartridges by a technologist, (ii) 13 DCS panels (batch V005) used for clinic verification on G3 cartridges by a nurse or lay counselor, and (iii) 20 DCS panels (batch V005) used for the verification of 10 GeneXpert 16 module instruments in mobile vehicles on the G3 cartridge performed by a scientist. The stabilities of the DCSs over 6 months at 4°C, room temperature, and 37°C were investigated. The mean cycle threshold (CT) and standard deviation (SD) for probe A were calculated. The proportions of variability in the CT values across bulk batches, assay versions, and settings and cadre of staff were determined using regression analysis. Overall, the DCSs demonstrated SDs of 3.3 (n = 660) for the G3 cartridges and 3.8 (n = 1,888) for the G4 cartridges, with an overall error rate of 1.5% and false rifampin resistance rate of 0.1%. The proportions of variability (R(2)) in the CT values explained by batch were 14%, by setting and cadre of staff, 5.6%, and by assay version, 4.2%. The most stable temperature in a period of up to 6 months was 37°C (SD, 2.7). The DCS is a robust product suitable for storage, transport, and use at room temperature for the verification of the GeneXpert instrument, and the testing can be performed by non-laboratory-trained personnel in nonlaboratory settings.

Entities:  

Mesh:

Year:  2013        PMID: 24068004      PMCID: PMC3838079          DOI: 10.1128/JCM.01715-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  5 in total

1.  Dried culture spots for Xpert MTB/RIF external quality assessment: results of a phase 1 pilot study in South Africa.

Authors:  L E Scott; N Gous; B E Cunningham; B D Kana; O Perovic; L Erasmus; G J Coetzee; H Koornhof; W Stevens
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

2.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

4.  Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.

Authors:  Kathryn Schnippel; Gesine Meyer-Rath; Lawrence Long; William MacLeod; Ian Sanne; Wendy S Stevens; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2012-06-12       Impact factor: 2.622

5.  The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro.

Authors:  Bavesh D Kana; Bhavna G Gordhan; Katrina J Downing; Nackmoon Sung; Galina Vostroktunova; Edith E Machowski; Liana Tsenova; Michael Young; Arseny Kaprelyants; Gilla Kaplan; Valerie Mizrahi
Journal:  Mol Microbiol       Date:  2008-02       Impact factor: 3.501

  5 in total
  9 in total

1.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

2.  A pilot evaluation of external quality assessment of GenoType MTBDRplus versions 1 and 2 using dried culture spot material.

Authors:  N Gous; L E Isherwood; A David; W Stevens; L E Scott
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

Review 3.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

4.  Genetic Mimetics of Mycobacterium tuberculosis and Methicillin-Resistant Staphylococcus aureus as Verification Standards for Molecular Diagnostics.

Authors:  Edith Erika Machowski; Bavesh Davandra Kana
Journal:  J Clin Microbiol       Date:  2017-09-20       Impact factor: 5.948

5.  Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay.

Authors:  Natasha Gous; Lesley Scott; Leigh Berrie; Wendy Stevens
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

6.  South Africa's experience with provision of quality HIV diagnostic services.

Authors:  Natasha M Gous; Leigh Berrie; Patience Dabula; Wendy Stevens
Journal:  Afr J Lab Med       Date:  2016-10-17

7.  The Development of a Standardized Quality Assessment Material to Support Xpert® HIV-1 Viral Load Testing for ART Monitoring in South Africa.

Authors:  Lara Dominique Noble; Lesley Erica Scott; Asiashu Bongwe; Pedro Da Silva; Wendy Susan Stevens
Journal:  Diagnostics (Basel)       Date:  2021-01-22

8.  A global proficiency testing programme for Xpert® MTB/RIF using dried tube specimens, 2013-2015.

Authors:  Katherine Klein; Kyle DeGruy; Zilma Rey; Patricia Hall; Andrea Kim; Steve Gutreuter; Heather Alexander
Journal:  Afr J Lab Med       Date:  2020-11-27

9.  Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions.

Authors:  Wendy Stevens; Natasha Gous; Nathan Ford; Lesley E Scott
Journal:  BMC Med       Date:  2014-09-08       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.